Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies (DMTs) have been approved by the US Food and Drug Administration (FDA) for the treatment of relapsing forms of MS, DMT costs continue to rise. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Christine, Anderson, James, Ganguly, Tanmoy, Prescott, James, Capila, Ishan, Lansing, Jonathan C., Sachleben, Richard, Iyer, Mani, Fier, Ian, Roach, James, Storey, Kristina, Miller, Paul, Hall, Steven, Kantor, Daniel, Greenberg, Benjamin M., Nair, Kavita, Glajch, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144347/
https://www.ncbi.nlm.nih.gov/pubmed/28847230
http://dx.doi.org/10.1177/0897190017725984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144347/
https://www.ncbi.nlm.nih.gov/pubmed/28847230
http://dx.doi.org/10.1177/0897190017725984

Ejemplares similares